Chaveli-L—pez B. Oral toxicity produced by chemotherapy: A systematic review. J Clin Exp Dent. 2014;6(1):e81-90.

 

doi:10.4317/jced.51337

http://dx.doi.org/doi:10.4317/jced.51337

 

References

1. Ruiz-Esquide G, Nervi B, Vargas A, Ma’z A. Treatment and prevention of cancer treatment related oral mucositis. Rev Med Chil. 2011;139:373-81.

http://dx.doi.org/10.4067/S0034-98872011000300015

PMid:21879172                                                                   

                                                                     

2. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011;47:441-8.

http://dx.doi.org/10.1016/j.oraloncology.2011.03.028

PMid:21514211                                                                   

                                                                     

3. L—pez-Galindo MP, Bag‡n JV, JimŽnez-Soriano Y, Alpiste F, Camps C. Clinical evaluation of dental and periodontal status in a group of oncological patients before chemotherapy. Med Oral Patol Oral Cir Bucal. 2006;11:E17-21.

PMid:16388287                                                                   

                                                                     

4. Chaveli L—pez B, Gavald‡ Esteve C, Sarri—n PŽrez MG. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2011;3:e31-42.

http://dx.doi.org/10.4317/jced.3.e31                                                        

                                                                     

5. CaribŽ-Gomes F, Chimenos-KŸstner E, L—pez-L—pez J, Finestres-Zubeldia F, Guix-Melcior B. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003;83:178-87.                                                               

PMID: 12730652

                                                                     

6. L—pez-Casta-o F, O-ate-S‡nchez RE, Rold‡n-Chicano R, Cabrerizo-Merino MC. Measurement of secondary mucositis to oncohematologic treatment by means of different scale. Review. Med Oral Patol Oral Cir Bucal. 2005;10:412-21.     

PMID: 16264377                               

                                                                     

7. Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC. Oral complications in Chinese cancer patients undergoing chemotherapy. Support Care Cancer. 2003;1:48-55.                                                            

PMID: 12527954

                                                                     

8. Mosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in the treatment of cancer patients. Oral Dis. 2011;17:550-9.

http://dx.doi.org/10.1111/j.1601-0825.2011.01788.x

PMid:21306481                                                                   

                                                                     

9. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820-31.

http://dx.doi.org/10.1002/cncr.22484

PMid:17236223                                                                   

                                                                     

10. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39-44.

http://dx.doi.org/10.1067/moe.2002.126018

PMid:12193891                                                                   

                                                                     

11. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma. 2003;44:1165-72.

http://dx.doi.org/10.1080/1042819031000079159

PMid:12916869                                                                   

                                                                     

12. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978.

PMid:17943748                                                                   

                                                                     

13. Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol. 2008;19:1644-9.

http://dx.doi.org/10.1093/annonc/mdn179

PMid:18453519                                                                   

                                                                     

14. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007;109:322-31.

http://dx.doi.org/10.1002/cncr.22384

PMid:17154160                                                                   

                                                                     

15. Innocenti M, Moscatelli G, Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage. 2002;24:456-7.

http://dx.doi.org/10.1016/S0885-3924(02)00524-9                                                        

PMID: 12547044

                                                                     

16. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:753-9.

http://dx.doi.org/10.1007/s10096-010-1148-z

PMid:21225303                                                                   

                                                                     

17. Avşar A, Elli M, Darka O, Pinarli G. Long-term effects of chemotherapy on caries formation, dental development, and salivary factors in childhood cancer survivors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:781-9.

http://dx.doi.org/10.1016/j.tripleo.2007.02.029

PMid:17618135                                                                   

                                                                     

18. Oğuz A, Cetiner S, Karadeniz C, Alpaslan G, Alpaslan C, Pinarli G. Long-term effects of chemotherapy on orodental structures in children with non-Hodgkin's lymphoma. Eur J Oral Sci. 2004;112:8-11.

http://dx.doi.org/10.1111/j.0909-8836.2004.00094.x

PMid:14871187                                                                   

                                                                     

19. Rojas-Morales T, Lugo Z, Santana Y, Navas R, Zambrano O, Viera N, et al. Capacity buffer of the saliva in children and adolescents with cancer: Variations induced by the administration of Metotrexate or Cyclophosphamide. Med Oral Patol Oral Cir Bucal. 2005;10:E103-8.

PMid:15995568                                                                   

                                                                     

20. Cowart BJ. Taste dysfunction: a practical guide for oral medicine. Oral Dis. 2011;17:2-6.

http://dx.doi.org/10.1111/j.1601-0825.2010.01719.x

PMid:20796233                                                                   

                                                                     

21. Sepœlveda E, Brethauer U, Rojas J, Fern‡ndez E, Le Fort P. Oral ulcers in children under chemotherapy: clinical characteristics and their relation with Herpes Simplex Virus type 1 and Candida albicans. Med Oral Patol Oral Cir Bucal. 2005;10:E1-8.

PMid:15800462                                                                   

                                                                     

22. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009;1:CD006706.

PMid:19160295                                                                   

                                                                     

23. Walling DM, Flaitz CM, Nichols CM. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J Infect Dis. 2003;188:883-90.

http://dx.doi.org/10.1086/378072

PMid:12964120                                                                   

                                                                     

24. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136:1117-24.

http://dx.doi.org/10.1007/s00432-010-0907-7

PMid:20508948                                                                   

                                                                     

25. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365-83.

http://dx.doi.org/10.1007/s00774-010-0162-7

PMid:20333419                                                                   

                                                                     

26. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.

http://dx.doi.org/10.1016/S0278-2391(03)00720-1                                                        

PMID: 12966493

                                                                     

27. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.

http://dx.doi.org/10.1016/j.joms.2004.02.004

PMid:15122554                                                                   

                                                                     

28. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.

http://dx.doi.org/10.1111/j.1600-0714.2004.00269.x

PMid:15641993                                                                   

                                                                      

29. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.

http://dx.doi.org/10.1016/j.joms.2006.11.003

PMid:17307580                                                                   

                                                                     

30. Bag‡n J, Blade J, Cozar JM, Constela M, Garc’a Sanz R, G—mez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.

PMid:17664922                                                                   

                                                                     

31. G—mez Font R, Mart’nez Garc’a ML, Olmos Mart’nez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 2008;13:E318-24.

PMid:18449117                                                                   

                                                                     

32. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 2012;41:214-21.

http://dx.doi.org/10.1111/j.1600-0714.2011.01091.x

PMid:21958312                                                                   

                                                                     

33. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009;45:551-4.

http://dx.doi.org/10.1016/j.oraloncology.2009.01.002

PMid:19251474                                                                   

                                                                     

34. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009;35:119-30.

http://dx.doi.org/10.1111/j.1747-4477.2009.00213.x

PMid:19961450                                                                   

                                                                     

35. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis. 2009;15:527-37.

http://dx.doi.org/10.1111/j.1601-0825.2009.01581.x

PMid:19619192                                                                   

                                                                     

36. Chaveli L—pez B, Sarri—n PŽrez MG, JimŽnez Soriano Y. Dental considerations in pregnancy and menopause. J Clin Exp Dent. 2011;3:e135-44.

http://dx.doi.org/10.4317/jced.3.e135                                                     

                                                                     

37. Arduino PG, Menegatti E, Scoletta M, Battaglio C, Mozzati M, Chiecchio A, et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med. 2011;40:510-5.

http://dx.doi.org/10.1111/j.1600-0714.2010.01004.x

PMid:21251073                                                                   

                                                                     

38. Vescovi P. Bisphosphonates and osteonecrosis: an open matter. Clin Cases Miner Bone Metab. 2012;9:142-4.

PMid:23289026 PMCid:PMC3536000                                                      

                                                                     

39. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7-14.

http://dx.doi.org/10.1200/JOP.2.1.7

PMid:20871729 PMCid:PMC2794643                                                      

                                                                     

40. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol. 2012;48:753-7.

http://dx.doi.org/10.1016/j.oraloncology.2012.02.009

PMid:22401869